129 related articles for article (PubMed ID: 8137464)
1. Chronic oral etoposide in advanced breast cancer.
Palombo H; Estapé J; Viñolas N; Grau JJ; Mañé JM; Daniels M; Mellado B
Cancer Chemother Pharmacol; 1994; 33(6):527-9. PubMed ID: 8137464
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.
Martín M; Lluch A; Casado A; Santabárbara P; Adrover E; Valverde JJ; López-Martín JA; Rodriguez-Lescure A; Azagra P; García-Conde J
J Clin Oncol; 1994 May; 12(5):986-91. PubMed ID: 8164052
[TBL] [Abstract][Full Text] [Related]
3. Daily oral etoposide in metastatic breast cancer.
Nesković-Konstantinović ZB; Bosnjak SM; Radulović SS; Mitrović LB
Anticancer Drugs; 1996 Jul; 7(5):543-7. PubMed ID: 8862722
[TBL] [Abstract][Full Text] [Related]
4. Phase II study with etoposide in previously untreated advanced breast cancer.
Wander HE; Rauschning W; Meyer D; Achterrath W; Nagel GA
Cancer Chemother Pharmacol; 1989; 24(4):261-3. PubMed ID: 2752508
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral etoposide for patients with advanced breast cancer.
Atienza DM; Vogel CL; Trock B; Swain SM
Cancer; 1995 Dec; 76(12):2485-90. PubMed ID: 8625074
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.
Martín M; Casado A; Lluch A; Adrover E; Diaz-Rubio E; García-Conde J
Cancer Treat Rev; 1993; 19 Suppl C():47-52. PubMed ID: 8221716
[TBL] [Abstract][Full Text] [Related]
7. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.
Pusztai L; Walters RS; Valero V; Theriault RL; Hortobagyi GN
Am J Clin Oncol; 1998 Oct; 21(5):442-6. PubMed ID: 9781596
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.
Bontenbal M; Planting AS; Verweij J; de Wit R; Kruit WH; Stoter G; Klijn JG
Breast Cancer Res Treat; 1995 May; 34(2):185-9. PubMed ID: 7647335
[TBL] [Abstract][Full Text] [Related]
9. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.
Saphner T; Weller EA; Tormey DC; Pandya KJ; Falkson CI; Stewart J; Robert NJ
Am J Clin Oncol; 2000 Jun; 23(3):258-62. PubMed ID: 10857889
[TBL] [Abstract][Full Text] [Related]
10. Chronic oral etoposide in non-small cell lung carcinoma.
Estapé J; Palombo H; Sánchez-Lloret J; Agustí C; Grau JJ; Daniels M; Viñolas N; Solá C; Biete A; Ramirez J
Eur J Cancer; 1992; 28A(4-5):835-7. PubMed ID: 1326308
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.
Valabrega G; Berrino G; Milani A; Aglietta M; Montemurro F
Breast J; 2015; 21(3):241-5. PubMed ID: 25772707
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma.
Cox EB; Burton GV; Olsen GA; Vugrin D
Am J Clin Oncol; 1989 Feb; 12(1):53-6. PubMed ID: 2643295
[TBL] [Abstract][Full Text] [Related]
13. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results.
Calvert AH; Lind MJ; Millward MM; Cantwell BM; Gumbrell L; Proctor M; Simmons D; Chapman F; Robinson A; Charlton C
Cancer Treat Rev; 1993; 19 Suppl C():27-33. PubMed ID: 8221713
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
[TBL] [Abstract][Full Text] [Related]
15. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy.
Yuan P; Xu BH; Wang JY; Ma F; Fan Y; Li Q; Zhang P
Chin Med J (Engl); 2012 Mar; 125(5):775-9. PubMed ID: 22490573
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
[TBL] [Abstract][Full Text] [Related]
17. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
18. Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients.
Jagodic M; Cufer T; Zakotnik B; Cervek J
Anticancer Drugs; 2001 Mar; 12(3):199-204. PubMed ID: 11290866
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
20. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
